Última actualización 6 de julio de 2026
Key finding
GLS improved by 1.06 ± 1.83% (P < 0.01)
This study compared the effects of empagliflozin and pioglitazone on echocardiographic indices in patients with type 2 diabetes and nonalcoholic fatty liver disease, finding significant improvements in certain measures.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study compared the effects of empagliflozin and pioglitazone on echocardiographic indices in patients with type 2 diabetes and nonalcoholic fatty liver disease, finding significant improvements in certain measures.
These findings are significant as they suggest that both empagliflozin and pioglitazone can positively impact heart and liver health in patients with type 2 diabetes and nonalcoholic fatty liver disease. This could lead to better management of these conditions and improved patient outcomes.
Limited sample size may affect generalizability. Short duration of follow-up may not capture long-term effects. Potential confounding factors not fully controlled.
Published in
Publication details and source links for this paper.
Fereshte A, Sepideh E, Masoudreza S, et al. A Comparison between the Effect of Empagliflozin and Pioglitazone on Echocardiographic Indices in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. BMC Gastroenterology. 2023;23:327. doi:10.1186/s12876-023-02948-4
Empagliflozin improved global longitudinal strain by 1.06 ± 1.83% (P < 0.01).
Pioglitazone improved global longitudinal strain by 1.56 ± 2.34% (P < 0.01).
Controlled attenuation parameter improved by -48.22 ± 35.02 dB/m (P = 0.01) with empagliflozin.
Liver stiffness measure decreased significantly by -1.11 ± 1.33 kPa (P < 0.01) without substantial difference between groups.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Empagliflozin, Pioglitazone and Controlled attenuation parameter, Global longitudinal strain, Liver stiffness measure.
This study contributes evidence to
Primary intervention
Empagliflozin
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
3
Related topics
6
Evidence pairs
85
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Tema de evidencia
matched_outcome
Evidencia relacionada
Tema de evidencia
Guardar evidencia
Core evidence
The primary outcomes reported in this study.
Empagliflozin → Controlled attenuation parameter
Empagliflozin → Controlled attenuation parameter
Empagliflozin → Global longitudinal strain
Empagliflozin → Global longitudinal strain
Empagliflozin → Liver stiffness measure
Empagliflozin → Liver stiffness measure
Pioglitazone → Controlled attenuation parameter
Pioglitazone → Controlled attenuation parameter
Pioglitazone → Global longitudinal strain
Pioglitazone → Global longitudinal strain
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Thiazolidinediones and Controlled attenuation parameter, Thiazolidinediones and Liver stiffness measure.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring Controlled attenuation parameter
Measures Controlled attenuation parameter as a key outcome.
All studies measuring Liver stiffness measure
Measures Liver stiffness measure as a key outcome.
All studies on Thiazolidinediones
Contributes to Thiazolidinediones evidence base.
Jump to pre-filtered views in Evidence Explorer.
2 results
2 results
2 results
2 results
2 results
Generated from the study's connected evidence using Evidence Intelligence™.
Pioglitazone may improve Controlled attenuation parameter.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Ranked evidence signals
Controlled attenuation parameter
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
Current evidence does not show a clear benefit of Pioglitazone for Liver stiffness measure.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Liver stiffness measure
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | neutral | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Empagliflozin appears to improve Controlled attenuation parameter.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Controlled attenuation parameter
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Empagliflozin appears to improve Global longitudinal strain.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Global longitudinal strain
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Centrada en la evidencia, no en la publicidad.
Tus datos siempre están protegidos.
Se agregan nuevos estudios todos los días.
